406 related articles for article (PubMed ID: 19072352)
1. Balsalazide disodium for the treatment of ulcerative colitis.
Patil SA; Moss AC
Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):177-84. PubMed ID: 19072352
[TBL] [Abstract][Full Text] [Related]
2. Balsalazide in treating colonic diseases.
Tursi A
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1555-63. PubMed ID: 19708827
[TBL] [Abstract][Full Text] [Related]
3. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
Tursi A
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S119-22. PubMed ID: 18806701
[TBL] [Abstract][Full Text] [Related]
4. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
5. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.
Wiggins JB; Rajapakse R
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1279-84. PubMed ID: 19743890
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
7. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
[TBL] [Abstract][Full Text] [Related]
8. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
9. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
Hanauer SB
Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.
Rahimi R; Nikfar S; Rezaie A; Abdollahi M
Dig Dis Sci; 2009 Apr; 54(4):712-21. PubMed ID: 18683049
[TBL] [Abstract][Full Text] [Related]
11. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Muijsers RB; Goa KL
Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
[TBL] [Abstract][Full Text] [Related]
12. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
13. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
Safdi AV; Cohen RD
Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
[TBL] [Abstract][Full Text] [Related]
14. Review article: the management of mild to severe acute ulcerative colitis.
Travis SP
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():88-92. PubMed ID: 15352901
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
[TBL] [Abstract][Full Text] [Related]
16. Pyostomatitis vegetans: A clinical marker of silent ulcerative colitis.
Markiewicz M; Suresh L; Margarone J; Aguirre A; Brass C
J Oral Maxillofac Surg; 2007 Feb; 65(2):346-8. PubMed ID: 17236948
[No Abstract] [Full Text] [Related]
17. Review article: aminosalicylates in inflammatory bowel disease.
Hanauer SB
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
[TBL] [Abstract][Full Text] [Related]
18. MMX mesalamine.
Baker DE
Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
[TBL] [Abstract][Full Text] [Related]
19. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
20. Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
Hanauer SB
Aliment Pharmacol Ther; 2008 Mar; 27 Suppl 1():15-21. PubMed ID: 18307645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
